14.2 Glycemic Control Monotherapy Trials in Adults with Type 2 Diabetes Mellitus In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or metformin 1500 to 2000 mg/day following a two-week washout
Hesselink, M
Blood 115 , 20572064 (2010)
Combining a high dose of oral PL7737 with dual GIPR/GLP-1R agonist tirzepatide caused DIO rats to lose 15% of their body weight compared to vehicle control after four days of treatment, an additive effect compared to either treatment alone (138)
GHK-Cu therapy may be appropriate if you: Have visible skin aging, such as fine lines, wrinkles, or loss of firmness Struggle with thinning hair, scalp changes, or poor hair density Experience delayed wound healing or fragile skin after injury or procedures Want physician-monitored support for skin, scalp, or tissue repair Are otherwise healthy but seeking evidence-informed, non-surgical rejuvenation
